CD21loCXCR3+ B cells and CD21loCXCR3+CD11c+ B cells were likewise significantly enriched in eMS→SMSA outcomes versus healthy controls and all non-MS outcomes (healthy controls plus eMS→LTNA outcomes, n = 13), though differences between eMS→LTNA and eMS→SMSA outcomes were not significant (Figure 5, D and E). Here, ITGAX is linked to myeloid sarcoma.